Depo-Medrol (methylprednisolone) suspension 40 mg/ml. 1ml. vial №1


Manufacturer: Belgium



The use of glucocorticoids should only be considered as symptomatic treatment, in addition to the presence of certain endocrine disorders, when glucocorticoids are used as replacement therapy. For intramuscular administration Depo-Medrol is not indicated for the treatment of acute life-threatening conditions. If you need to get a rapid hormonal effect of maximum intensity, intravenous administration of a viscocorticoid, such as methylprednisolone sodium succinate (solu-Medrol), is indicated. If oral therapy is not possible and this drug is indicated for the treatment of the disease, Depo-Medrol is used intramuscularly, as indicated below. Anti-inflammatory treatment Rheumatic disease. As an adjunct to maintenance therapy (analgesics, kinesotherapy, physiotherapy, etc.) and for short-term use (to bring the patient out of an acute state or with an exacerbation of the process) in psoriatic arthritis, ankylosing spondylitis. For the following indications, preference should be given (if possible) to in situ administration: post-traumatic osteoarthritis, synovitis in osteoarthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (in some cases, maintenance therapy with low doses may be necessary), acute and subacute bursitis, epicondylitis, acute nonspecific tendosinovitis, acute gouty arthritis. Collagenosises. During exacerbation or as maintenance therapy in some cases for systemic lupus erythematosus, systemic dermatomyositis (polymyositis), acute rheumatic carditis. Dermatology diseases. Pemphigus, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, fungal mycosis, bullous herpetiform dermatitis (sulfoni are first – choice drugs, and systemic use of glucocorticoids is an auxiliary treatment). Allergic condition. To control severe or disabling allergic diseases that cannot be treated with appropriate standard therapy methods: chronic asthmatic respiratory diseases, contact dermatitis, atopic dermatitis, serum sickness, seasonal or year-round allergic rhinitis, drug Allergy, transfusion reactions by the type of urticaria, acute non-infectious laryngeal edema (epinephrine is the first choice drug). Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes affecting the eyes and nearby organs, such as eye damage caused by Herpes zoster, iritis, iridocyclitis, chorioretinitis, diffuse posterior uveitis, optic neuritis. Gastro-intestinal diseases. To remove the patient from a critical condition in the case of ulcerative colitis, Crohn’s disease (systemic therapy). Edema of the condition. To stimulate diuresis or induce remission in proteinuria in nephrotic syndrome without uremia-an idiopathic type, or caused by systemic lupus erythematosus. Diseases of the respiratory system. Symptomatic sarcoidosis of the respiratory system, berylliosis, fulminant or disseminated pulmonary tuberculosis (when used simultaneously with appropriate anti-TB chemotherapy), Leffler syndrome, which cannot be treated with other methods, aspiration pneumonitis. Treatment of hematological and oncological diseases Hematological diseases. Acquired (autoimmune) hemolytic anemia, secondary thrombocytopenia in adults, erythroblastopenia (erythrocytic anemia), congenital (erythroid) hypoplastic anemia. Oncological disease. For palliative treatment of leukemia or lymphoma in adults, acute leukemia in children. Endocrine disease Primary or secondary adrenal insufficiency, acute adrenal insufficiency (hydrocortisone or cortisone are the drugs of choice; if necessary, their synthetic analogues can be used in combination with mineralocorticoids; in early childhood, obtaining mineralocorticoids is especially important), congenital adrenal hyperplasia, hypercalcemia associated with a malignant tumor, non-purulent thyroiditis. Diseases of other organs and systems. Tuberculosis meningitis with subarachnoid or threatening block (use simultaneously with the appropriate anti-TB chemotherapy), trichinellosis involving the nervous system or myocardium. On the part of the nervous system: the period of exacerbation of multiple sclerosis. For intrasynovial, periarticular, intrabursal or soft tissue injection (see also section ” application features») Depo-Medrol is indicated as an adjunctive therapy for short-term use (to remove the patient from an acute state or with an exacerbation of the process) for such diseases: synovitis in osteoarthritis, rheumatoid arthritis, acute and subacute bursitis, acute gouty arthritis, epicondylitis, acute nonspecific tenosynovitis, posttraumatic osteoarthritis. For introduction to the pathological focus Depo-Medrol is indicated for administration to a pathological focus for such diseases: keloids, localized hypertrophic, infiltrated foci of inflammation (flat lichen, psoriatic plaques, ring-shaped granuloma, simple chronic lichen (limited neurodermatitis), discoid lupus erythematosus, alopecia nervosa. Depo-Medrol can also be effective in the treatment of cystic formations, aponeurosis or tendinitis (ganglia). For installation in the rectum. Ulcerative colitis.